SG10201700808UA - Trk-INHIBITING COMPOUND - Google Patents

Trk-INHIBITING COMPOUND

Info

Publication number
SG10201700808UA
SG10201700808UA SG10201700808UA SG10201700808UA SG10201700808UA SG 10201700808U A SG10201700808U A SG 10201700808UA SG 10201700808U A SG10201700808U A SG 10201700808UA SG 10201700808U A SG10201700808U A SG 10201700808UA SG 10201700808U A SG10201700808U A SG 10201700808UA
Authority
SG
Singapore
Prior art keywords
trk
inhibiting compound
inhibiting
compound
Prior art date
Application number
SG10201700808UA
Inventor
Jun Takeuchi
Satoshi Itadani
Kazuya Hashimura
Masahiro Ikura
Masato Higashino
Tetsuya Yasuhiro
Takeshi Nagaura
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG10201700808UA publication Critical patent/SG10201700808UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201700808UA 2013-02-19 2014-02-18 Trk-INHIBITING COMPOUND SG10201700808UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013029563 2013-02-19
JP2013141246 2013-07-05

Publications (1)

Publication Number Publication Date
SG10201700808UA true SG10201700808UA (en) 2017-02-27

Family

ID=51391222

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506514QA SG11201506514QA (en) 2013-02-19 2014-02-18 Trk-INHIBITING COMPOUND
SG10201700808UA SG10201700808UA (en) 2013-02-19 2014-02-18 Trk-INHIBITING COMPOUND

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201506514QA SG11201506514QA (en) 2013-02-19 2014-02-18 Trk-INHIBITING COMPOUND

Country Status (22)

Country Link
US (6) US9463192B2 (en)
EP (3) EP3800183A1 (en)
JP (4) JP5954486B2 (en)
KR (1) KR20150118148A (en)
CN (3) CN104995172B (en)
AU (3) AU2014219855B2 (en)
BR (3) BR122017003181A2 (en)
CA (1) CA2901332A1 (en)
DK (1) DK2960234T3 (en)
ES (2) ES2710556T3 (en)
HK (1) HK1213261A1 (en)
HU (1) HUE042591T2 (en)
IL (3) IL240602A0 (en)
MX (3) MX362181B (en)
NZ (1) NZ711119A (en)
PH (3) PH12015501799A1 (en)
PL (1) PL2960234T3 (en)
PT (1) PT2960234T (en)
RU (1) RU2667907C9 (en)
SG (2) SG11201506514QA (en)
TW (3) TWI567067B (en)
WO (1) WO2014129431A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (en) 2008-09-22 2014-06-09 Array Biopharma Inc Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
ES2900243T3 (en) 2008-10-22 2022-03-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
MX2012013467A (en) 2010-05-20 2013-04-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors.
RU2667907C9 (en) 2013-02-19 2019-01-31 Оно Фармасьютикал Ко., Лтд. Trk-inhibiting compound
WO2016021629A1 (en) 2014-08-06 2016-02-11 塩野義製薬株式会社 Heterocyclic and carbocyclic derivative having trka-inhibiting activity
MX2017002199A (en) 2014-08-18 2017-08-18 Ono Pharmaceutical Co ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND.
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA41667A1 (en) 2015-06-01 2018-08-31 Loxo Oncology Inc Method for diagnosing and treating cancer
WO2017006953A1 (en) 2015-07-07 2017-01-12 塩野義製薬株式会社 HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
KR102482200B1 (en) * 2016-01-27 2022-12-27 우니페르지타에트 취리히 Use of GAA receptor modulators for the treatment of pruritus
JP6898043B2 (en) 2016-02-04 2021-07-07 塩野義製薬株式会社 Nitrogen-containing heterocycles and carbocyclic derivatives with TrkA inhibitory activity
JPWO2017155018A1 (en) * 2016-03-11 2019-01-17 小野薬品工業株式会社 Trk inhibitor resistant cancer therapeutic agent
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
CA3019671C (en) 2016-04-04 2024-02-20 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR20180129911A (en) 2016-04-04 2018-12-05 록쏘 온콜로지, 인코포레이티드 How to treat pediatric cancer
PL3458456T3 (en) 2016-05-18 2021-04-19 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
CN109890820B (en) * 2016-10-28 2020-11-03 正大天晴药业集团股份有限公司 Aminopyrazolopyrimidine compounds as neurotrophin tyrosine kinase receptor inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
EP3679932A1 (en) 2017-09-06 2020-07-15 ONO Pharmaceutical Co., Ltd. METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN117285467A (en) 2018-07-31 2023-12-26 罗索肿瘤学公司 Spray-dried dispersions and formulations
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
KR20210142154A (en) 2019-03-21 2021-11-24 옹쎄오 DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN117751121A (en) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 Crystals of aminopyrazolopyrimidine compounds
CN117597129A (en) * 2021-08-06 2024-02-23 正大天晴药业集团股份有限公司 Use of aminopyrazolopyrimidine compounds in the treatment of TRK kinase mediated tumors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
AU739642B2 (en) * 1997-12-22 2001-10-18 Bayer Healthcare Llc Inhibition of p38 kinase activity using substituted heterocyclic ureas
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
MXPA05009102A (en) 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Substituted pyridine derivatives useful in the treatment of cancer and other disorders.
JP2007535565A (en) * 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション Substituted pyrazolyl urea derivatives useful for the treatment of cancer
US7741479B2 (en) 2004-12-07 2010-06-22 Locus Pharmaceuticals, Inc. Urea inhibitors of MAP kinases
JP5197016B2 (en) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー Enzyme modulators and therapy
RU2368602C2 (en) 2005-01-26 2009-09-27 Айрм Ллк Compounds and compositions as protein kinase inhibitors
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
WO2007064872A2 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
DK1957073T3 (en) 2005-12-05 2014-05-12 Otsuka Pharma Co Ltd PHARMACEUTICAL
JP5142513B2 (en) * 2005-12-05 2013-02-13 大塚製薬株式会社 Medicine
TW200804349A (en) 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
AU2007236321A1 (en) 2006-04-12 2007-10-18 Merck Patent Gmbh N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2900404B1 (en) 2006-04-27 2008-07-18 Sod Conseils Rech Applic NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20120225057A1 (en) * 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
JP2010524970A (en) 2007-04-20 2010-07-22 デシフェラ ファーマシューティカルズ，エルエルシー Kinase inhibitors useful for the treatment of myeloproliferative disorders and other proliferative disorders
US20110129440A1 (en) 2007-10-29 2011-06-02 Schering Corporation Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US20120202818A1 (en) 2009-06-09 2012-08-09 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
AR077468A1 (en) * 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CN101717373B (en) * 2009-11-09 2012-06-20 东南大学 Diaryl urea derivative and application thereof
US8637516B2 (en) * 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2731439A4 (en) * 2011-07-12 2014-12-03 Merck Sharp & Dohme TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
JP2013029563A (en) 2011-07-27 2013-02-07 Sony Corp Display device and display method
KR20130076947A (en) 2011-12-29 2013-07-09 삼성전자주식회사 Imaging apparatus and control method for the same
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
RU2667907C9 (en) * 2013-02-19 2019-01-31 Оно Фармасьютикал Ко., Лтд. Trk-inhibiting compound
TWI672141B (en) 2014-02-20 2019-09-21 美商醫科泰生技 Molecules for administration to ros1 mutant cancer cells
MX2017002199A (en) 2014-08-18 2017-08-18 Ono Pharmaceutical Co ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND.

Also Published As

Publication number Publication date
CN106986857A (en) 2017-07-28
US9463192B2 (en) 2016-10-11
US10300060B2 (en) 2019-05-28
RU2015139590A (en) 2017-03-27
BR112015019921A2 (en) 2017-07-18
US20190231777A1 (en) 2019-08-01
DK2960234T3 (en) 2019-04-01
US9993479B2 (en) 2018-06-12
MX362181B (en) 2019-01-08
MX346411B (en) 2017-03-17
EP2960234B1 (en) 2018-12-19
AU2018282336A1 (en) 2019-01-17
EP3800183A1 (en) 2021-04-07
TWI567067B (en) 2017-01-21
CN106986857B (en) 2019-07-05
CA2901332A1 (en) 2014-08-28
EP3459935A1 (en) 2019-03-27
PH12016502582B1 (en) 2019-01-21
IL249517A0 (en) 2017-02-28
SG11201506514QA (en) 2015-09-29
WO2014129431A1 (en) 2014-08-28
IL249518B (en) 2020-05-31
AU2018282336B2 (en) 2019-10-03
JP2018039825A (en) 2018-03-15
IL240602A0 (en) 2015-10-29
AU2017279570B2 (en) 2018-10-25
PT2960234T (en) 2019-02-15
EP2960234A4 (en) 2016-07-13
US9498453B2 (en) 2016-11-22
US20170340634A1 (en) 2017-11-30
HK1213261A1 (en) 2016-06-30
PH12016502581B1 (en) 2019-01-21
TW201437206A (en) 2014-10-01
JP2016138121A (en) 2016-08-04
TWI663161B (en) 2019-06-21
IL249517B (en) 2020-04-30
JP5954486B2 (en) 2016-07-20
US10765676B2 (en) 2020-09-08
US20180256573A1 (en) 2018-09-13
NZ711119A (en) 2020-08-28
PH12015501799B1 (en) 2015-11-09
CN104995172A (en) 2015-10-21
TW201716392A (en) 2017-05-16
TW201623283A (en) 2016-07-01
HUE042591T2 (en) 2019-07-29
JP6528957B2 (en) 2019-06-12
BR122017003181A2 (en) 2019-09-10
EP3459935B1 (en) 2020-12-23
JP6233454B2 (en) 2017-11-22
AU2014219855B2 (en) 2017-09-28
US9763943B2 (en) 2017-09-19
RU2667907C9 (en) 2019-01-31
CN104995172B (en) 2017-05-31
PH12015501799A1 (en) 2015-11-09
JPWO2014129431A1 (en) 2017-02-02
EP2960234A1 (en) 2015-12-30
BR122017003188A2 (en) 2019-09-10
ES2710556T3 (en) 2019-04-25
AU2017279570A1 (en) 2018-01-18
MX2015010742A (en) 2016-01-08
IL249518A0 (en) 2017-02-28
PH12016502581A1 (en) 2019-01-21
TWI567068B (en) 2017-01-21
US20170027939A1 (en) 2017-02-02
RU2667907C2 (en) 2018-09-25
JP2016196479A (en) 2016-11-24
ES2853485T3 (en) 2021-09-16
US20160000783A1 (en) 2016-01-07
CN106928197A (en) 2017-07-07
KR20150118148A (en) 2015-10-21
US20160280684A1 (en) 2016-09-29
AU2014219855A1 (en) 2015-09-10
PL2960234T3 (en) 2019-04-30
MX353336B (en) 2018-01-09
JP5954510B1 (en) 2016-07-20
PH12016502582A1 (en) 2019-01-21

Similar Documents

Publication Publication Date Title
IL249518A0 (en) Trk-inhibiting compound
HK1222393A1 (en) Novel quinoline-substituted compound
GB201311891D0 (en) Novel compound
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201302368D0 (en) Compound
HK1219100A1 (en) Pyridinylpyrazoloquinoline compound
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201312901D0 (en) Compounds
EP2947066A4 (en) Phenoxyalkylamine compound
EP3010923A4 (en) Pyrroloquinazoline compounds
EP2948457A4 (en) Compounds
GB201307331D0 (en) Compound
GB201408643D0 (en) Compound
GB201310460D0 (en) Compounds
GB201306794D0 (en) Compounds
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound
GB201322855D0 (en) Compounds
GB201303572D0 (en) New Compound
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds